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The primary aim of this study was to assess the ultrasonographic features of hip joints in pa-
tients with mucopolysaccharidosis (MPS) type I and II in comparison with healthy popula-
tion. The secondary aims were to correlate these features with clinical measures and to
evaluate the utility of ultrasound in the diagnosis of MPS disease.
Materials and Methods
SixteenMPS I (n = 3) and II (n = 13) patients were enrolled in the present study and underwent
clinical and radiological evaluation, and bilateral high-resolution ultrasonography (US) of hip
joints. The distance from the femoral neck to joint capsule (synovial joint space, SJS), joint effu-
sion, synovial hyperthrophy, and local pathological vascularization were evaluated. The results
were compared to the healthy population and correlated with clinical and radiological measures.
Results
1. There was a difference in US SJS between children with MPS disease and the normative
value for healthy population (7mm). Mean values of SJS were 15.81 ± 4.08 cm (right hip
joints) and 15.69 ± 4.19 cm (left joints). 2. No inflammatory joint abnormalities were detected
in MPS patients. 3. There was a clear correlation between US SJS and patients’ age and
height, while no clear correlation was observed between SJS and disease severity.
Conclusions
1. Patients with MPS I and II present specific features in hip joint ultrasonography. 2. The
data suggests that ultrasonography might be effective in the evaluation of hip joint involve-
ment in patients with MPS and might present a valuable tool in facilitating the diagnosis and
follow up of the disease.
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Introduction
Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders caused by a defi-
cient activity of enzymes responsible for the catabolism of glycosaminoglycans (GAGs) leading
to a short stature and severe joint and bone disease [1]. Mucopolysaccharidosis type I (MPS I)
is caused by a deficient activity of alpha-L-iduronidase (IDUA; EC 3.2.1.76) and is divided into
three subtypes based on the severity of symptoms: Hurler syndrome (severe, OMIM 607016),
Hurler–Scheie syndrome (intermediate, OMIM 607015), and Scheie syndrome (attenuated,
OMIM 607016) [1–3]. Mucopolysaccharidosis type II (MPS II, Hunter disease, OMIM
309900) is an X-linked recessive disorder caused by a deficiency of iduronate-2-sulfatase (IDS,
EC 3.1.6.13). Hunter syndrome affects primarily males while females are non-manifesting car-
riers of the condition [1].
MPS disorders are characterized by severe skeletal abnormality including growth failure, ab-
normal bone structure (dysostosis multiplex), and severe articular cartilage and joint disease be-
cause glycosaminoglycans are fundamental in connective tissue formation, structure and
function. The underlying cause of degenerative joint and bone disease is a lack of skeletal re-
modeling, disordered endochondral and intramembranous ossification, disruption of normal
elastogenesis and the infiltration by GAGs of the ligaments, tendons, joint capsules and other
tissue structures [4–6]. GAG storage in MPS induces a complex sequence of molecular abnor-
malities leading to inflammation, apoptosis (cartilage), and hyperplasia (synovial membranes),
resulting in poorly organized and metabolically abnormal connective tissue matrices [7–10].
Mucopolysaccharidoses are traditionally evaluated by conventional radiography due to spe-
cific changes in the structure and shape of bones. The use of musculoskeletal ultrasound (US)
in rheumatology clinical practice allows rheumatologists to diagnose, prognosticate and moni-
tor disease outcome in rheumatoid arthritis [11–13]. It has proven earlier assessment of synovi-
al, cartilage and bone abnormalities than conventional radiology. Numerous studies have also
demonstrated that ultrasonographic examination of joints is more sensitive than clinical physi-
cal examination [14]. Despite this, there are no studies about the ultrasound investigation of
joints in patients with MPS disease.
This is the first ultrasound study of hip joints in mucopolysaccharidoses. The primary aim of
this study was to assess the ultrasonographic features of hip joints in patients with MPS type I and
II in comparison with healthy population. The secondary aims were to correlate these features
with disease severity and to evaluate the utility of ultrasound in the diagnosis of MPS disease.
Material and Methods
The study objectives were as follows
1. to assess the ultrasonographic features of hip joints in patients with MPS I and II in compar-
ison to healthy population
2. to assess the ultrasonographic features of hip joints in relation to disease severity in patients
with MPS I and II
3. to evaluate the utility of ultrasound in the diagnosis of MPS disease
Study subjects
We performed a prospective and cross-sectional study including 16 male patients (mean age
15.1 years) with a diagnosis of MPS I (n = 3, age 11 and 32 years) or II (n = 13, age range 6–34
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years) confirmed by biochemical and molecular analyses (Table 1). All patients were enrolled
at the Department of Pediatrics, St. Louis Regional Children’s Hospital, Cracow, Poland.
Methods
The US evaluation in all patients was performed bilaterally on hip joints. Ultrasound images
were obtained with a Philips model HD 11 XE with a 7.5–12 MHz liner transducer (accuracy
0.1 mm). A standardized procedure similar to that used by other investigators was followed
[11,12], a ventral, longitudinal approach was chosen for the hip [11,12].
The following features were assessed: femoral necks, joint cavity, joint capsule (shape,
course, thickness, adhesion to femoral neck and head), the distance between femoral neck and
joint capsule (the so-called synovial joint space, SJS), echogenicity of joint capsules, synovial
fluid (presence or lack of thereof), synovial hyperthrophy, and joint vascularization (using
Color Doppler and Power Doppler).
All MPS patients were evaluated on a gray scale of echogenicity and compared to the
healthy children.
Both Color Doppler and Power Doppler were used in all patients (PD and CD settings: PRF
0.5–0.9 kHz, gain setting (dynamic range) 20–40 db, frequency 500 Hz, color box (color gain)
18–30 dB) [15].
Ultrasonography in all MPS patients was performed by the same pediatric rheumatologist
trained in musculoskeletal US.
Statistical analysis
The normative value of distance from the femoral neck to joint capsule is 7 mm (as published
by the Polish Ultrasonographic Society and Outcome Measures in Rheumatoid Arthritis Clini-
cal Trial (OMERACT) [16–18]). Mean values and standard deviation of SJS of hip joints were
Table 1. Demographic characteristics of 16 patients with mucopolysaccharidoses.
Patient Disease Patient’s weight Patient’s height
(current age) (phenotype*) (kg) (cm)
1 (32) MPS II (attenuated) 56.3 149.3
2 (10) MPS II (severe) 40.0 133
3 (14) MPS II (severe) 38.4 136
4 (8) MPS II (severe) 32.4 122
5 (12) MPS II (severe) 26.7 122
6 (7) MPS II (severe) 24.1 120
7 (6) MPS II (severe) 26.0 112
8 (31) MPS II (attenuated) 47.0 151
9 (29) MPS II (attenuated) 46 150
10 (9) MPS II (severe) 25.0 123.5
11 (12) MPS II (severe) 24.0 120.2
12 (6) MPS II (severe) 25.5 124
13 (9) MPS II (severe) 23 121
14 (11) MPS I (Scheie) 30.0 138
15 (34) MPS I (Scheie) 70.0 171
16 (12) MPS I (Scheie) 27 143
*Disease classification/severity defined as MPS I—Hurler, Hurler-Scheie, Scheie; MPS II—severe = neuronopathic, attenuated = non-neuronopathic.
doi:10.1371/journal.pone.0123792.t001
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calculated for MPS patients. To compare the relationship between the variables such as body
weight, height and age ultrasonography values of SJS of hip joints, the linear correlation with
Pearson’s product-moment correlation coefficient was performed.
Ethical Consideration
The protocol was approved by the human-subjects institutional review board at St. Louis Hos-
pital (Ethics Committee, St. Louis Hospital, Cracow, Poland). Written informed consent had to
be provided by the parents or legal guardians.
Results
Ultrasonographic features of hip joints in patients with MPS I and II in
comparison to healthy population (Figs 1–6)
• all patients presented significantly thickened synovial joint space. Mean values of SJS were
15.81 ± 4.08 cm for right hip joints and 15.69 ± 4.19 cm for left joints. Mean values for both
joints were greater than the normative value in healthy population
• all patients presented significantly increased echogenicity of joint capsules in comparison to
healthy population
• none of the patients presented any signs of synovitis or increased flow through the joint
Ultrasonographic features of hip joints in relation to clinical measures in
patients with MPS I and II
• there was a positive correlation between value of SJS and patient’s height and age (Table 2)
• with age, both increase in SJS as well as echogenicity of joint capsule were observed
• no clear correlation was observed between disease severity and value of SJS
Fig 1. Ultrasound images of hip joints. (Left) Longitudinal scan of hip joint in a 14-year-old patient with a severe phenotype of MPS II. (Right) Longitudinal
scan of hip joint in a 14-year-old healthy child. Arrows shows differences in the distance from the femoral neck to joint capsule (synovial joint space, SJS).
doi:10.1371/journal.pone.0123792.g001
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Evaluation the utility of ultrasound in the diagnosis of MPS disease
• all patients presented specific ultrasonographic features different than healthy population as
well as patients with other rheumatological conditions such as significantly thickened SJS,
significantly increased echogenicity of joint capsules, no signs of synovitis or increased flow
through the joint
Discussion
Cartilage is the major area of pathology in mucopolysaccharidoses, leading to poor bone
growth, poor joint mobility and painful joints [7,8,10]. Due mainly to lysosomal deposition of
GAGs in the chondrocytes, the extracellular matrix of the articular cartilage, the synovia, and
Fig 2. Ultrasound images of hip joints. (Left) Transverse scan of hip joint a 14-year-old patient with a severe phenotype of MPS II. (Right) Longitudinal
scan of hip joint in a 14-year-old healthy child. Arrows shows differences in the distance from the femoral neck to joint capsule (synovial joint space, SJS).
doi:10.1371/journal.pone.0123792.g002
Fig 3. Ultrasound and X-ray images of hip joints. (Left) Transverse scan of hip joint a 12-year-old patient with a severe phenotype of MPS II. (Right)
Radiograph of the pelvis of a 12-year-old patient with a severe phenotype of MPS II: dysostosis multiplex (irregular shape of the pelvis, hypoplastic hip
acetabulum, dysplastic hips, osteonecrosis of the femoral heads with flattened acetabula, lopsided head of femur bones).
doi:10.1371/journal.pone.0123792.g003
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Fig 4. Ultrasound images of hip joints. (Left) Longitudinal scan of hip joint in a 32-year-old patient with an attenuated phenotype of MPS II. (Right)
Longitudinal scan of hip joint in a 10-year-old patient with a severe phenotype of MPS II.
doi:10.1371/journal.pone.0123792.g004
Fig 5. The results of Pearson’s correlation between values of synovial joint space (right joint capsule) and patients’ age and height.
doi:10.1371/journal.pone.0123792.g005
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the surrounding tissues, MPS patients have stiff joints, contractures and poor mobility [19].
Simonaro et al hypothesized that lysosomal and/or extracellular GAG storage in the MPS dis-
orders induce inflammation and affect the growth of connective tissue cells and other cell types
by activating the Toll-like receptor 4 (TLR4) signaling pathway [6]. TLR4 activation in MPS
animals resulted in the production of ceramide, a pro-apoptotic lipid and the release of numer-
ous inflammatory cytokines and proteases [9]. Stimulation of MPS connective tissue cells by
the inflammatory cytokines causes enhanced secretion of several of the matrix
Fig 6. The results of Pearson’s correlation between values of synovial joint space (left joint capsule) and patients’ age and height.
doi:10.1371/journal.pone.0123792.g006
Table 2. The results of Pearson’s correlation between values of synovial joint space and patients’ age
and height.
variable age (years) body height
right joint capsule Pearson’s r 0.88 0.66
N 16.00 15.00
p value 0.00 0.01
left joint capsule Pearson’s r 0.85 0.64
N 16.00 15.00
p value 0.00 0.01
doi:10.1371/journal.pone.0123792.t002
Ultrasonography of Hip Joints in MPS I and II
PLOS ONE | DOI:10.1371/journal.pone.0123792 April 29, 2015 7 / 10
metalloproteinases (MMPs). The imbalance of MMPs over tissue inhibitors of metalloprotei-
nase, the TIMPs, precipitate features of both osteoarthritis as well as rheumatoid arthritis in
joints of MPS patients [20].
Mucopolysaccharidoses are traditionally evaluated by conventional radiography. It detects
dysostosis multiplex, which is a clinical hallmark of almost all different types of MPS with the
exception of MPS III [21]. However, some inflammatory and/or primary degenerative joint
diseases may mimic the radiologic and clinical findings of MPSs. Also, radiography may be un-
able to catch early disease signs and depict articular cartilage, especially in attenuated cases. Ul-
trasound can overcome this barrier since it can visualize articular hyaline cartilage as a well-
defined anechoic band lacking internal echoes [22]. Ultrasound can also show pathological
signs of articular cartilage in terms of thickness, transparency, and sharpness as well as depict a
range of abnormalities from the minimally thickened synovium to severe hyperthrophy with
fluid, debris and villi. Owing to better axial and lateral resolution of US, even minute bone sur-
face abnormalities may be depicted. Thus destructive and/or reparative/hypertrophic changes
on the bone surface may be seen before they are apparent on plain x rays or even magnetic res-
onance imaging [23]. Doppler ultrasound additionally allows the visualization of microvascu-
larity within joint cavity and periarticular tissue providing information about the presence or
absence of flow through the joint. Musculoskeletal ultrasound has nowadays become an estab-
lished imaging technique for the diagnosis and follows up of patients with rheumatic diseases.
Despite this, so far, there are no studies about the ultrasound investigation of joints in patients
with MPS disease.
Our data confirm usefulness of US in imaging MPS changes in hip joints of patients with
MPS disease. All patients, regardless of disease progression, presented specific ultrasonographic
findings such as significantly thickened synovial joint space with significantly increased echo-
genicity, and no signs of synovitis or increased flow through the joint. Thickening of the syno-
vial joint space was not dependent on disease severity, but rather length of the disease process.
Disease severity is assessed clinically and is associated with mental retardation, while thicken-
ing of the SJS is a result of glycosaminoglycan storage in the joints.
Our findings suggest that ultrasonography of hip joints might be effective in the evaluation
of hip joint involvement in patients with MPS I and II and might be useful in facilitating the
differential diagnosis of MPS disease with other rheumatic diseases, follow up of these diseases
and assessment of efficacy of the treatment. Further studies are needed to confirm it. Because
bone and joint manifestations and skeletal abnormalities are early and prominent features of
MPSs, even in attenuated and mild patients, sooner or later (but fairly often before their under-
lying illness has been recognized) rheumatologists play a key role in disease recognition and
timely diagnosis [24,25]. Consequently, it is important that rheumatologists are aware of the
clinical manifestations that could be related to MPS diseases, what else to look for and what di-
agnostic procedures are available [24]. Ultrasonography has considerable advantages over
other imaging methods, including non-invasiveness, speed of performance, relatively low costs,
ability to scan multiple joints, repeatability, and high patient acceptability [26]. US of hip joints
in older children as well as adults could be included into the diagnostic algorithm of patients
with musculoskeletal symptoms.
Conclusions
1. Patients with MPS I and II present specific features in hip joint ultrasonography.
2. The presence of these features should lead to the suspicion of MPS disease.
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